Phase 2 N=131 Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
Neurotrophic Keratitis
Primary: Efficacy as Assessed by Complete Corneal Healing — 21; 16 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib
Idiopathic Pulmonary Fibrosis · Diarrhoea
Primary: Achievement of Diarrhoea Control at Week 12 Follow-up While Taking the Optimal Nintedanib Dose — 70.59 Percentage of participants
Phase 3 N=362 Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia Subjects
Presbyopia · Near Vision · Refractive Error
Primary: Number of Participants With at Least One Treatment-Related TEAE — 101; 75; 17 Participants
N/A N=120 Study to Evaluate the Effectiveness of Test Dentifrice in the Relief of Dentinal Hypersensitivity
Dentin Sensitivity
Primary: Adjusted Mean Change From Baseline in Schiff Sensitivity Score at Week 12 (Test Dentifrice Versus [vs] Negative Control Dentifrice) — -1.19; -0.44 score on a scale…
Phase 2 N=128 KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 5.4; 11.1; 4.4 Percentage of participants
Phase 3 N=168 Effects of Dexmedetomidine on Delirium Duration of Non-intubated ICU Patients (4D Trial)
Delirium · Agitation
Primary: Duration of Agitation (in Hours), Defined by a RASS ≥ +1 — 1; 2 hours
Phase 2 N=194 Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Pancreatic Cancer
Primary: Progression-free Survival (PFS) - Biomarker Enriched Population — 5.5; 7.3; 5.9 months
Phase 2 N=260 A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed
Influenza, Human · Influenza in Birds · Respiratory Tract Infections
Primary: Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HI) Antibodies Against the H5N6 Strain — 5.48; 5.55; 5.47; 20.39 titer
Phase 2 N=89 Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.
Lung Cancer · Lung Metastases
Primary: Clinically Significant Events (CSE) — 0.449 Proportion of subjects — p=<.0001
N/A N=102 Dietary Approaches to Stop Hypertension for Diabetes
Diabetes Mellitus, Type 2 · Diabetes · Diabetes type2
Primary: Systolic Blood Pressure (SBP) — 122.4; 127.2; 124.8; 127.0 mmHg — p=<0.001
N/A N=300 Dynamically Tailored Behavioral Interventions in Diabetes
Type 2 Diabetes
Primary: Mean HbA1c Value — 9.84; 10.17; 8.91; 9.23 % of hemoglobin bound to glucose — p=0.0085
Phase 1 N=96 Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)
Healthy
Primary: Percentage of Subjects With Drug Related Adverse Events (AEs) in Part I — 46.7; 50.0; 44.4; 66.7 Percentage of participants
N/A N=50 TOF Monitoring Using the TetraGraph in Patients Less Than 1 Year of Age
Surgery
Primary: TOFr (%) — 99; 95 percent
Phase 1 N=7 A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)
Mature B-cell Neoplasms
Primary: Number of Participants Who Experience Dose Limiting Toxicities (DLTs) Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version…
N/A N=40 Sleep Apnoea Breathing Record Exploratory Study (SABRES)
Sleep Apnea
Primary: Correlation Between the Trial Device and an Established Device — 0.955 correlation coefficient